Recently, we have shown that morphine's analgesic activity can be attenuated by chemokines, specifically CCL5 and CXCL12. Because the HIV-1 coat protein, glycoprotein 120 (gp120), binds to the same receptors as do CCL5 and CXCL12, experiments were designed to investigate the effect of gp120 in the brain on antinociception induced by morphine in the cold-water (À3°C) tail-flick (CWT) and hot-plate (+54°C) tests. In addition, mu-opioid-receptor-mediated effects in brain periaqueductal grey (PAG) slices were examined with whole-cell patch-clamp recordings. The results showed that (1) pretreatment with gp120 itself (10, 25, 50, 100 or 133 ng, PAG) had no nociceptive effect in the CWT; (2) pretreatment with gp120 (25 or 100 ng) dose-dependently reduced antinociception induced by subcutaneous (sc) injection of morphine (3 or 6 mg/kg) or PAG injection of morphine (100 ng) in the CWT; (3) a PAG injection of gp120 (133 ng), given 30 min before sc injection of morphine (6 mg/kg), similarly reduced morphine antinociception in the hot-plate test; (4) the inhibitory effect of gp120 on morphine-induced antinociception in the CWT was reversed by AMD3100, an antagonist of CXCR4; (5) pretreatment of slices with gp120 (200 pM) prevented morphine (10 lM)-induced hyperpolarization and reduction of input resistance in PAG neurons. Electrophysiology studies paralleled gp120-induced desensitization of a mu-opioid-receptor-mediated response in PAG neurons at the single-cell level. These studies are the first to demonstrate that the analgesic activity of morphine can be reduced by the presence of gp120 in the PAG and that pretreatment with AMD3100 is able to restore the analgesic effects of morphine.
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Introduction
Various pain syndromes have been reported in human immunodeficiency virus type 1 (HIV-1)-infected individuals. Most of these patients require medication for appropriate pain control. Although the opioids, particularly morphine, remain the best option for treating acute and chronic severe pain, they are less effective in treating some types, such as inflammatory and neuropathic pain. The entrance of HIV-1 into susceptible cells by fusion of the viral membrane with the cell plasma membrane (Dimitrov, 2000) is generally initiated by the binding of the HIV-1 envelope glycoprotein gp120 to CD4 on the host cell surface. The conformational change of the gp120 then allows it to interact with cellular surface chemokine receptors (coreceptors), of which the most common types are the CC chemokine receptor 5 (CCR5) and the CXC chemokine receptor 4 (CXCR4) (Shimizu et al., 2000; Berger et al., 1999; He et al., 1997) . Chemokines are a superfamily of small cytokine-like molecules that have the ability to mediate the migration of various cell types. CXCL12/SDF-1alpha binds primarily to one receptor, CXCR4, although it can also bind to CXCR7 (Hartmann et al., 2008; Thelen and Thelen, 2008) . CXCR4 binds only CXCL12, whereas CCL5/RANTES binds primarily to CCR5 but also to other receptors (CCR1 and CCR3) (Murphy et al., 2000) . CXCR4 was expressed in several cell types in brain, but notably in neurons and microglia (Lavi et al., 1997; Shieh et al., 1998; Tanabe et al., 1997) . The chemokines CCL5 or CXCL12 and their receptors have been reported to be involved in blocking the analgesic effects of opioids (Adler et al., 2006) . Our laboratories were the first to report an apparent in vivo inactivation of opioid receptors by chemoattractant factors (Szabo et al., 2002) . Pretreatment with CCL5 or CXCL12 can block the antinociceptive effect of DAM-GO, a selective l-opioid receptor agonist, or morphine (Adler and Rogers, 2005; Szabo et al., 2002) .
The effects of opioids such as morphine are mediated through the opioid receptors. Opioid receptors are widely expressed both peripherally and in the CNS (Chen et al., 1993; Evans et al., 1992) . The opioid agonist morphine has been shown to amplify the effect of the tubular cell-gp120 interaction on the proliferation of kidney fibroblasts (Singhal et al., 1998) and to potentiate
